# MediTrust Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meditrust-health

- Industry: Financial Services
- Headquarters: Shanghai, China
- Website: www.meditrusthealth.com
- Total disclosed funding: $463M
- Latest round: Series C (Aug 9, 2021)
- Investors on record: 17

## About

Founded in 2017 by Seth Zhang and John Ho, and based in Shanghai, China, MediTrust Health operates as a medical financing company that helps patients with their medical payments and insurance measures. The company has branches in Beijing and Shenzhen, and has a partnership with over 50 drug makers and 2000 pharmacy stores, nearly 4,000 DTP pharmacies, over 70 pharmaceutical companies and 80 insurance companies as of 2021. In August 2021, MediTrust Health raised CNY 2 billion in Series C funding by Boyu Capital, Janchor Partners, China International Capital Corporation, B Capital Group, Bank of China Group Investment, China International Capital Corporation, Everbright Private Equity and Lilly Asia Ventures. The company has 56 employees as of July 2021.

The company offers digital healthcare payment services that focus on medical, providing commercial insurance, installment payments, medicines payment, and other services. MediTrust's Care2Pay platform is a healthcare payment and care service platform that offers both online care and medical management services and provides access to affordable medications to patients with chronic and rare conditions who have limited insurance coverage. The company's iCare Internet Hospital lends access to patients for new drugs and novel therapies and the Clover Care Center provides health management services, drug benefits, education activities and insurance products. Through its Kangfu Zhibao health insurance platform, the company helps insurers in launching products in multiple cities. MediTrust also operates the Yaokangfu platform that serves patients with tumors, chronic diseases and rare diseases.

## Funding rounds

- Series C, Aug 9, 2021, $309M — China International Capital Corporation, Bank of China Group Investment, Lilly Asia Ventures, China Everbright, Sinovation Ventures, Boyu Capital, China Renaissance, Janchor Partners, Marathon Venture Partners, B Capital, Shanghai Biopharmaceutical Investment Fund
- Series B, Mar 5, 2021, $154M — SAIF Partners, NLVC, Sinovation Ventures, China Renaissance, Shanghai Industrial Investment (Holdings), Ant Group, Marathon Venture Partners, BioTrack Capital
- Series A, Apr 2, 2019 — SAIF Partners, BioTrack Capital
- Angel, Apr 11, 2018 — Eight Roads Ventures, Marathon Venture Partners

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Angel
- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Angel, Series B, Series C
- SAIF Partners (https://capitalatlas.ai/funds/saif-partners) — Series A, Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A, Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series B, Series C
- China Renaissance (https://capitalatlas.ai/funds/china-renaissance) — Series B, Series C
- Shanghai Industrial Investment (Holdings) — Series B
- Ant Group (https://capitalatlas.ai/funds/ant-group) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Bank of China Group Investment — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series C
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series C
- Janchor Partners — Series C
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series C
- Shanghai Biopharmaceutical Investment Fund — Series C